Table III.

Correlation between DHX32 protein expression and clinicopathological characteristics of patients with breast cancer.

Characteristic	Low DHX32 expressiona	High DHX32 expressiona	χ2	P-value
Age (years)				0.539
≤50	38	49	0.378
≥50	51	55
Tumor size (cm)				0.275
≤2	59	61	1.190
≥2	30	43
Histological grade				0.029b
I–II	60	54	4.761
III	29	50
Clinical stage				0.006c
I–II	68	60	7.518
III–IV	21	44
Lymph node metastasis				<0.001c
Negative	69	48	19.776
Positive	20	56
Estrogen receptor status				0.815
Negatived	40	45	0.055
Positivee	49	59
Progesterone receptor status				0.795
Negatived	35	39	0.068
Positivee	54	65
HER-2 status				0.344
Negatived	65	71	0.897
Positivee	23	34
Ki-67 expression				0.004c
Negatived	37	23	8.475
Positivee	52	81

^aHigh or low DHX32 expression was determined by immunohistochemistry analysis.

^bP<0.05

^cP<0.01, as calculated using the Pearson's χ² and Fisher's exact tests.

^dAbsent or weak staining was categorized as negative.

^eModerate or strong staining was categorized as positive. DHX32, DEAH-box helicase 32; HER2, human epidermal growth factor receptor-2; Ki-67, marker of proliferation Ki-67.